Esperion Therapeutics, Inc. · NASDAQ:ESPR
Esperion Therapeutics — Q1 2025 Earnings Presentation
19 slides from Esperion Therapeutics's earnings presentation, May 6, 2025
Slide 1: Q1 2025 Earnings Presentation
Q1 2025 Earnings Presentation May 6, 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved.
Slide 2: Forward-looking Statements & Disclosures
Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational
Slide 3: Business Update
Business Update Sheldon Koenig, President and CEO
Slide 4: Clear Strategic Plan for Success
Clear Strategic Plan for Success Expand Bempedoic Acid Reach Sustainable Operating Portfolio Expansion and Pipeline Franchise Globally Profitability Advancement Strong and consistent prescription Revenue growth, operating efficiency Our strengthened balance sheet demand and increasing physician and
Slide 5: Driving U.S. and Global Growth and Reaching Profitability
Driving U.S. and Global Growth and Reaching Profitability
Slide 6: Q1 2025 Performance
Q1 2025 Performance TOTAL REVENUE U.S. NET PRODUCT SALES $65.0M $34.9M +63% growth +41% growth -53% adjusting for one time settlement decrease agreement milestone with DSE received in Q1 2024 6 © 2024 Esperion. All Rights Reserved – Do not copy or distribute.
Slide 7: Expanding Access and Strengthening Clinical Validation
Expanding Access and Strengthening Clinical Validation Market Access Over 30 major healthcare plans removed prior authorizations, adopted electronic step Wins edits, and expanded formulary coverage. NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) added Clinical Validation to
Slide 8: Q1 2025 Script Trends and Drivers
Q1 2025 Script Trends and Drivers Quarterly Franchise RPE Trend Q1 2025 script growth grew 2% compared to Q4 2024, 220,000 reflecting a flat lipid-lowering market due to seasonal 200,000 +2% headwinds: 180,000 • Changes in Medicare Part D 160,000 • Higher out-of-pocket costs as patients need to meet
Slide 9: Oral Triple Combination
Oral Triple Combination Triple PCSK9i4 Ezetimibe2 Obicetrapib3 Combo1 Approval Status In development Approved/Generic In development 3 approved products LDL-C reduction ~ 60% - 70% 19% 33% ~ 48% - 71% Administration Dosing Once daily Once daily Once daily Bi-weekly to 6 months Oral CETP inhibitor no
Slide 10: Strategic Partnerships Driving Global Reach
Strategic Partnerships Driving Global Reach Approved in Maximizing Global Reach Across Key Regions 40 countries Japan Australia & Canada globally Europe Asia & South America Israel New Zealand Otsuka Pharmaceutical Co., Evaluating Partner Partner Daiichi Sankyo Europe Daiichi Sankyo Co., Ltd. Neopha
Slide 11: International Growth Continues at Strong Pace
International Growth Continues at Strong Pace 500,000 450,000 ~472,500 patients through 400,000 Feb’25 350,000 300,000 250,000 200,000 150,000 100,000 50,000 - Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, Switzerland, Ital
Slide 12: Pipeline Advancement
cSPERION Pipeline Advancement
Slide 13: Proven Science, Innovative Pipeline
Proven Science, Innovative Pipeline Innovative Portfolio & Pipeline LEAD PRECLINICAL CLINICAL APPROVED / PRODUCT/PROGRAM EXPLORATORY LEAD ID OPTIMIZATION DEVELOPMENT DEVELOPMENT COMMERCIAL MILESTONES Cardiovascular Disease (LDL-C lowering / CV Risk reduction) NEXLETOL® Approved 2020 bempedoic acid E
Slide 14: >$1B Annual Market Opportunity Estimate
High Unmet Need Driving Significant Market Opportunity PSC: A Rare and Progressive Liver Disease >$1B Annual Market Opportunity Estimate Diagnosed Prevalence of PSC • No approved therapies with proven efficacy to cure or halt PSC progression 30K3-5 • Potential Orphan Drug Designation & Fast Track Ap
Slide 15: Financial Update
Financial Update Ben Halladay, Chief Financial Officer
Slide 16: Q1 2025 Financial Highlights
Q1 2025 Financial Highlights TOTAL REVENUE COLLABORATION REVENUE $65.0M U.S. NET PRODUCT SALES $30.1M -53% decrease -73% decrease $34.9M +63% growth +41% growth +97% growth Adjusting for one time settlement Adjusting for one time settlement agreement milestone with DSE agreement milestone with DSE r
Slide 17: Important Safety Information
Important Safety Information
Slide 18: NEXLETOL Important Safety Information
NEXLETOL® Important Safety Information • NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred. • Hyperuricemia: NEXLETOL may increase blood uric acid le
Slide 19: NEXLIZET Important Safety Information
NEXLIZET® Important Safety Information • NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe or bemped
Esperion Therapeutics — Q1 2025 Earnings Presentation on 6ix